Effect of ipragliflozin on endothelial dysfunction in patients with type 2 diabetes and chronic kidney disease: A randomized clinical trial (PROCEED).
Tanaka A, Okada Y, Torimoto K, Kamei N, Hirai H, Kono T, Sugimoto K, Teragawa H, Taguchi I, Maruhashi T, Sonoda S, Kurozumi A, Inagaki S, Oshita C, Hisauchi I, Takahashi K, Higashi Y, Shimabukuro M, Node K; PROCEED Trial Investigators.
Tanaka A, et al. Among authors: sonoda s.
Diabetes Metab. 2023 Jul;49(4):101447. doi: 10.1016/j.diabet.2023.101447. Epub 2023 Apr 26.
Diabetes Metab. 2023.
PMID: 37116858
Clinical Trial.
No abstract available.